Search
LIC-477
go.drugbank.com/drugs/DB05363ExperimentalLIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.
PPI-2458
go.drugbank.com/drugs/DB05864InvestigationalThis class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases … PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets.
ETC-1001
go.drugbank.com/drugs/DB05866ExperimentalETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
SNS-314
go.drugbank.com/drugs/DB06134InvestigationalProliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death.
IMM-101
go.drugbank.com/drugs/DB15850InvestigationalStudies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. … It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023].
Nomacopan
go.drugbank.com/drugs/DB14991InvestigationalNomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).
Brolamfetamine
go.drugbank.com/drugs/DB01484ExperimentalIllicitCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAeroLEF
go.drugbank.com/drugs/DB05000InvestigationalAeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain. … AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia
S-8510
go.drugbank.com/drugs/DB06504ExperimentalS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
N-Methylmesoporphyrin
go.drugbank.com/drugs/DB01911ExperimentalThis compound belongs to the porphyrins. … This medication is known to target ferrochelatase.